News and Events
Stay up to date with news and events
Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
The pharmaceutical company Novartis has released a community update which announces that they are ending development of branaplam, a huntingtin lowering drug, for possible treatment…
Map-HD Registry has the first 100 participants!
Thank you to each and every person who signed up! Read the full article here.
uniQure gets the green light to resume testing HD gene therapy
In August 2022, uniQure announced a pause in new recruitment for their trial of AMT-130, an HD gene therapy delivered via brain surgery. The decision…
Update on the PTC Therapeutics PIVOT-HD Trial
Recruitment of participants into the US arm of the PTC Therapeutics PIVOT-HD trial has been paused. Since this announcement, there have been a lot of…
Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
In the past week or so, during and following a big HD research conference, two companies developing medicines for Huntington’s disease announced news about their…